Skip to main content
Download PDF
  • Research Article
  • Open access
  • Published:

Association of serum paraoxonase activity with lipid profile, APO-A and APO-B in subjects with different levels of HDL

Artery Research volume 24, pages 32–39 (2018)Cite this article

Abstract

Background

Coronary heart diseases are inversely related to plasma high-density lipoprotein (HDL) level. Paraoxonase-1 (PON1) is mainly associated with HDL and plays a vital role in protection of low-density lipoprotein (LDL) and HDL. The aim of this study was to investigate the association between paraoxonase activity (PON1) with lipid profile, apoA-I, apoB and apoB/apoA-I ratio in subjects with different level of HDL cholesterol (HDL-C).

Methods

135 subjects, 20–60 years old, contributed to this study. The subjects were divided into three groups (45 in each group) with different levels of HDL-C (High, Normal and Low). For each group, the activity of PON1 was measured using paraoxon as a substrate. Moreover, the serum level of lipid profile, ApoA and apoB were measured. The statistical analysis was performed using SPSS software.

Results

PON-1 activity and apoA-I level were decreased in subjects with lower level of HDL-C (P < 0.001). ApoB and apoB/apoA-I ratio were higher in subjects with lower level of HDL-C (P < 0.001). Serum PON-1 activity was positively correlated with TC, TG, apo A-B, and LDL-C levels (P < 0.01).

Conclusions

In conclusion, determination of serum PON1 activity and lipoproteins may play important role in earlier prediction of CAD and help to design a therapeutic for treatment of CAD toward PON1 activity regulation.

References

  1. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, et al. Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction. World Health Organization definition of myocardial infarction: 2008–09 revision. Int J Epidemiol 2011;40:139–46.

    Google Scholar 

  2. Landmesser U. Coronary artery disease: HDL and coronary heart disease–novel insights. Nat Rev Cardiol 2014;11(10): 559–60.

    Google Scholar 

  3. Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL. Front Pharmacol 2015;6:222. https://doi.org/10.3389/ fphar.2015.00222.

  4. Mackness M, Mackness B. Chapter 11 – Current aspects of paraoxonase-1 research. In: Komoda Tsugikazu, editor. The HDL Handbook. 2nd ed. Academic Press; 2014. p. 273–91. https://www.sciencedirect.com/science/article/pii/B9780124078673000111.

  5. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498–507.

    Google Scholar 

  6. Eren E, Yilmaz N, Aydin O. Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis. Cholesterol 2013;2013:792090. https://doi.org/10.1155/2013/792090.

  7. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL-C than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 2006; 187:74e1–74e10.

  8. Bajaj P, Tripathy RK, Aggarwal G, Pande AH. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli. Protein Expr Purif 2015;115:95–101.

    Google Scholar 

  9. Gaidukov L, Viji RI, Yacobson S, Rosenblat M, Aviram M, Tawfik DS. ApoE induces serum paraoxonase PON1 activity and stability similar to ApoA-I. Biochemistry 2010 Jan 26;49(3): 532–5.

  10. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein associated paraoxonase 1 (PON1) is essential for PON1- mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006;281:7657–65.

    Google Scholar 

  11. Perła-Kajan J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids 2012 Oct;43(4):1405–17.

    Google Scholar 

  12. Kulka M. A review of paraoxonase 1 properties and diagnostic applications. Pol J Vet Sci 2016; 19(1):225–32.

    Google Scholar 

  13. Sun T, Hu J, Yin Z, Xu Z, Zhang L, Fa L, et al. Low serum paraoxonase1 activity levels predict coronary artery disease severity. Oncotarget 2017;8(12):19443–54. https://doi. org/10.18632/oncotarget.14305.

  14. Gupta N, Binu KB, Singh S, Maturu NV, Sharma YP, Bhansali A, et al. Low serum PON1 activity: an independent risk factor for coronary artery disease in North-West Indian type 2 diabetics. Gene 2012 Apr 25;498(1):13–9.

  15. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapińska E, Majda J, Kustrzeba-Wójcicka I, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Adv Clin Exp Med 2013;22(2):229–36.

    Google Scholar 

  16. Sztanek F, Seres I, Harangi M, Lőcsey L, Padra J, Paragh GJ, et al. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease. Nephrol Dial Transplant 2012;27(7):2866–72.

    Google Scholar 

  17. Van Himbergen TM, van Tits LJ, Hectors MP, de Graaf J, Roest M, Stalenhoef AF. Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia. Biochem Biophys Res Commun 2005;333(3):787–93.

    Google Scholar 

  18. Wang M, Lang X, Cui S, Zou L, Cao J, Wang S, et al. Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA Cell Biol 2012;31(6):975–82.

    Google Scholar 

  19. Cheraghi M, Shahsavari G, Maleki A, Ahmadvand H. Paraoxonase 1 activity, lipid profile, and atherogenic indexes status in coronary heart disease. Rep Biochem Mol Biol 2017; 6(1):1–7.

    Google Scholar 

  20. Saha N, Roy AC, Teo SH, Tay JS, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991;40:277–82.

    Google Scholar 

  21. Rozek LS, Hatsukami TS, Richter RJ, Ranchalis J, Nakayama K, McKinstry LA, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 2005;46(9):1888–95.

    Google Scholar 

  22. Tietge UJ. Hyperlipidemia and cardiovascular disease: inflammation, dyslipidemia, and atherosclerosis. Curr Opin Lipidol 2014;25(1):94–5.

    Google Scholar 

  23. Landmesser U. Coronary artery disease: HDL and coronary heart disease-novel insights. Nat Rev Cardiol 2014; 11 (10): 559–60.

  24. Tan MH. HDL-cholesterol: the negative risk factor for coronary heart disease. Ann Acad Med Singapore 1980 Oct;9(4):491–5.

    Google Scholar 

  25. Ragbir S, Farmer JA. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 2010;12(5):343–8.

    Google Scholar 

  26. Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006;47:515–20.

    Google Scholar 

  27. Eren E, Yilmaz N, Aydin O. High density lipoprotein and it’s dysfunction. Open Biochem J 2012;6:78–93.

    Google Scholar 

  28. Himbergen TM, Roest M, de Graaf J, Jansen EH, Hattori H, Kastelein JJ, et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 2005;46:445–51.

    Google Scholar 

  29. Siewert S, Gonzalez II, Lucero RO, Ojeda MS. Association of cholesteryl ester transfer protein genotypes with paraoxonase-1 activity, lipid profile and oxidative stress in type 2 diabetes mellitus: a study in San Luis, Argentina. J Diabetes Investig 2015;6(1):67–77.

    Google Scholar 

  30. Fridman O, Fuchs AG, Porcile R, Morales AV, Gariglio LO. Paraoxonase: its multiple functions and pharmacological regulation. Archivos de Cardiologia de Mexico 2011;81(3):251–60.

    Google Scholar 

  31. Ferr‘e N, Camps J, Fernàndez-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 2003;49(9):1491–7.

    Google Scholar 

  32. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005;46:1239–47.

    Google Scholar 

  33. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371–82.

    Google Scholar 

  34. Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005;44:11843–54.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

    Maryam Teimouri & Hashem Nayeri

Authors
  1. Maryam Teimouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hashem Nayeri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hashem Nayeri.

Rights and permissions

This is an open access article distributed under the CC BY-NC license https://doi.org/creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teimouri, M., Nayeri, H. Association of serum paraoxonase activity with lipid profile, APO-A and APO-B in subjects with different levels of HDL. Artery Res 24, 32–39 (2018). https://doi.org/10.1016/j.artres.2018.10.227

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.artres.2018.10.227

Keywords

Artery Research

ISSN: 1876-4401

Contact us